Dr. Coombe et al., LOW ANTICOAGULANT HEPARIN RETAINS ANTI-HIV TYPE-1 ACTIVITY IN-VITRO, AIDS research and human retroviruses, 11(11), 1995, pp. 1393-1396
Heparin is a potent inhibitor of HIV-1 replication, in addition to bei
ng a well-established inhibitor of blood coagulation. The major antico
agulant activity of heparin results from binding to the plasma protein
antithrombin (AT). The high-affinity binding site for AT is a specifi
c pentasaccharide sequence that is of low abundance and completely abs
ent from the majority of heparin chains. We have examined the anti-HIV
-1 activity of both conventional and low molecular weight heparins fra
ctionated according to affinity for AT. The high- and low-affinity fra
ctions, despite differing markedly in anticoagulant activity, are iden
tical in their ability to bind to the envelope glycoprotein of HIV-1,
and in their inhibitory effect on HIV-1 replication in vitro (EC(50) 1
and 8 mu g/ml for conventional and low molecular weight fractions, re
spectively). Our study shows that the anti-HIV activity of heparin is
independent of its antithrombin-mediated inhibition of coagulation pro
teases. Therefore, heparin preparations retaining full anti-HIV-1 acti
vity in vitro but with greatly reduced anticoagulant activity may be r
eadily produced for further clinical investigation in the prophylaxis
and therapy of HIV infection.